5. Akutt lymfoblastisk leukemi (ALL) og lymfoblastlymfom hos voksne

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-405.

Brown, P. A., Ji, L., Xu, X., Devidas, M., Hogan, L. E., Borowitz, M. J., Raetz, E. A., Zugmaier, G., ... Loh, M. L. (2021). Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA : the journal of the American Medical Association, 325(9), 833-842.

Burke, P. W., Hoelzer, D., Park, J. H., Schmiegelow, K., & Douer, D. (2020). Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion. ESMO Open, 5(5)

Chalandon, Y., Thomas, X., Hayette, S., Cayuela, J. M., Abbal, C., Huguet, F., Raffoux, E., Leguay, T., ... Group for Research on Adult Acute Lymphoblastic Leukemia (2015). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood, 125(24), 3711-9.

Cortelazzo, S., Ferreri, A., Hoelzer, D., & Ponzoni, M. (2017). Lymphoblastic lymphoma. Critical Reviews in Oncology/Hematology, 113, 304-317.

Dunleavy, K., Pittaluga, S., Shovlin, M., Steinberg, S. M., Cole, D., Grant, C., Widemann, B., Staudt, L. M., ... Wilson, W. H. (2013). Low-intensity therapy in adults with Burkitt's lymphoma. New England Journal of Medicine, 369(20), 1915-25.

Giebel, S., Czyz, A., Ottmann, O., Baron, F., Brissot, E., Ciceri, F., Cornelissen, J. J., Esteve, J., ... Nagler, A. (2016). Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 122(19), 2941-2951.

Gökbuget, N. (2013). How I treat older patients with ALL. Blood, 122(8), 1366-75.

Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M. S., ... Bargou, R. C. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood, 131(14), 1522-1531.

Hoelzer, D., Walewski, J., Dohner, H., Viardot, A., Hiddemann, W., Spiekermann, K., Serve, H., Duhrsen, U., ... Gokbuget, N. (2014). Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood, 124(26), 3870-9.

Jabbour, E., Sasaki, K., Ravandi, F., Huang, X., Short, N. J., Khouri, M., Kebriaei, P., Burger, J., ... Kantarjian, H. M. (2018). Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer, 124(20), 4044-4055.

Jæger, P. H., Quist-Paulsen, P. (2017). Behandlingsresultater for voksne med akutt lymfoblastisk leuekmi i Norge 2008-2015 [hovedoppgave] [s.l.]: [s.n.].

Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S., ... Advani, A. S. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(8), 740-53.

Malard, F., & Mohty, M. (2020). Acute lymphoblastic leukaemia. Lancet, 395(10230), 1146-1162.

Martell, M. P., Atenafu, E. G., Minden, M. D., Schuh, A. C., Yee, K. W., Schimmer, A. D., Gupta, V., & Brandwein, J. M. (2013). Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. British Journal of Haematology, 163(4), 458-64.

Martinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gokbuget, N., Topp, M. S., Fielding, A. K., Rambaldi, A., ... Stein, A. (2017). Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, 35(16), 1795-1802.

Maude, S. L. (2018). Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clinical advances in hematology & oncology : H&O, 16(10), 664-666.

McBride, A., Lathon, S. C., Boehmer, L., Augustin, K. M., Butler, S. K., & Westervelt, P. (2013). Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. Pharmacotherapy, 33(3), 295-303.

Patel, B., Kirkwood, A. A., Dey, A., Marks, D. I., McMillan, A. K., Menne, T. F., Micklewright, L., Patrick, P., ... Fielding, A. K. (2017). Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia, 31(1), 58-64.

Pfeifer, H., Wassmann, B., Bethge, W., Dengler, J., Bornhauser, M., Stadler, M., Beelen, D., Vucinic, V., ... Gmall Study Group (2013). Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia, 27(6), 1254-62.

Porkka, K., Koskenvesa, P., Lundan, T., Rimpilainen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., ... Lee, F. Y. (2008). Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood, 112(4), 1005-12.

Quist-Paulsen, P., Toft, N., Heyman, M., Abrahamsson, J., Griskevicius, L., Hallbook, H., Jonsson, O. G., Palk, K., ... Schmiegelow, K. (2020). T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia, 34(2), 347-357.

Roschewski, M., Dunleavy, K., Abramson, J. S., Powell, B. L., Link, B. K., Patel, P., Bierman, P. J., Jagadeesh, D., ... Wilson, W. H. (2020). Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. Journal of Clinical Oncology, 38(22), 2519-2529.

Saini, N., Marin, D., Ledesma, C., Delgado, R., Rondon, G., Popat, U. R., Bashir, Q., Hosing, C. M., ... Kebriaei, P. (2020). Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood, 136(15), 1786-1789.

Sasaki, K., Jabbour, E. J., Ravandi, F., Short, N. J., Thomas, D. A., Garcia-Manero, G., Daver, N. G., Kadia, T. M., ... Kantarjian, H. M. (2016). Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 122(23), 3650-3656.

Short, N. J., Jabbour, E., Sasaki, K., Patel, K., O'Brien, S. M., Cortes, J. E., Garris, R., Issa, G. C., ... Ravandi, F. (2016). Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 128(4), 504-7.

Toft, N., Birgens, H., Abrahamsson, J., Griskevicius, L., Hallbook, H., Heyman, M., Klausen, T. W., Jonsson, O. G., ... Schmiegelow, K. (2018). Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia, 32(3), 606-615.

Vora, A., Goulden, N., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., Moorman, A. V., & Wade, R. (2014). Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncology, 15(8), 809-18.